Stem Cell Transplant Complications Clinical Trial
Official title:
A Mixed Methods Study Investigating Complications, Outcomes and Family Experiences of Gastrostomy Feeding in Paediatric Allogeneic Bone Marrow Transplantation
NCT number | NCT04804631 |
Other study ID # | 19SH04 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 15, 2021 |
Est. completion date | May 1, 2023 |
Verified date | April 2024 |
Source | Institute of Child Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to assess the problems and a range of nutritional and clinical outcomes that occur with two feeding tubes used by children having a bone marrow transplant. Children and parents will also be interviewed to ask about their experiences of tube feeding.
Status | Completed |
Enrollment | 43 |
Est. completion date | May 1, 2023 |
Est. primary completion date | May 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Month to 13 Years |
Eligibility | Inclusion Criteria: - Admitted to the centre during the study period for an allogeneic bone marrow transplant (BMT) for any diagnosis. - Receiving any conditioning regimen, donor type and stem cell source. - Children admitted for their second or more BMT. - Children admitted on an established enteral tube feeding regimen. - NHS patients. Exclusion Criteria: - Children receiving first-line, prophylactic, parenteral nutrition as this is not the standard nutrition pathway of most children receiving BMT at the centre. This is usually given in specific circumstances such as children receiving cord blood transplants or those with gastrointestinal diseases. - Autologous BMT, including children receiving chimeric antigen receptor T-cell therapy (CAR-T). - No feeding tube placed and no nutrition support required from tube feeding or parenteral nutrition. Children rarely do not require any form of nutrition support. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Great Ormond Street Hospital | London |
Lead Sponsor | Collaborator |
---|---|
Institute of Child Health | Great Ormond Street Hospital for Children NHS Foundation Trust, National Institute for Health Research, United Kingdom |
United Kingdom,
Evans J, Needle JJ, Hirani SP. Early outcomes of gastrostomy feeding in paediatric allogenic bone marrow transplantation: A retrospective cohort study. Clin Nutr ESPEN. 2019 Jun;31:71-79. doi: 10.1016/j.clnesp.2019.02.014. Epub 2019 Mar 21. — View Citation
Gonzales F, Bruno B, Alarcon Fuentes M, De Berranger E, Guimber D, Behal H, Gandemer V, Spiegel A, Sirvent A, Yakoub-Agha I, Nelken B, Duhamel A, Seguy D. Better early outcome with enteral rather than parenteral nutrition in children undergoing MAC allo-SCT. Clin Nutr. 2018 Dec;37(6 Pt A):2113-2121. doi: 10.1016/j.clnu.2017.10.005. Epub 2017 Oct 12. — View Citation
Hoffmeister PA, Storer BE, Macris PC, Carpenter PA, Baker KS. Relationship of body mass index and arm anthropometry to outcomes after pediatric allogeneic hematopoietic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2013 Jul;19(7):1081-6. doi: 10.1016/j.bbmt.2013.04.017. Epub 2013 Apr 25. — View Citation
McGrath KH, Hardikar W. Gastrostomy tube use in children with cancer. Pediatr Blood Cancer. 2019 Jul;66(7):e27702. doi: 10.1002/pbc.27702. Epub 2019 Mar 11. — View Citation
Peric Z, Botti S, Stringer J, Krawczyk J, van der Werf S, van Biezen A, Aljurf M, Murray J, Liptrott S, Greenfield DM, Duarte RF, Ruutu T, Basak GW. Variability of nutritional practices in peritransplant period after allogeneic hematopoietic stem cell transplantation: a survey by the Complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant. 2018 Aug;53(8):1030-1037. doi: 10.1038/s41409-018-0137-1. Epub 2018 Mar 7. — View Citation
Trehan A, Viani K, da Cruz LB, Sagastizado SZ, Ladas EJ. The importance of enteral nutrition to prevent or treat undernutrition in children undergoing treatment for cancer. Pediatr Blood Cancer. 2020 Jun;67 Suppl 3:e28378. doi: 10.1002/pbc.28378. — View Citation
Williams-Hooker R, Adams M, Havrilla DA, Leung W, Roach RR, Mosby TT. Caregiver and health care provider preferences of nutritional support in a hematopoietic stem cell transplant unit. Pediatr Blood Cancer. 2015 Aug;62(8):1473-6. doi: 10.1002/pbc.25473. Epub 2015 Mar 21. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Weight Z-score | Change in weight Z-score between groups. Measured using ward scales. | Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to six months post-transplant (6 months) | |
Secondary | Gastrostomy tube complications | Categorical reporting of the incidence of any complications occurring with the gastrostomy tube e.g. infection, dislodgement, blockage | Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to tube removal or six months post-transplant, whichever comes first (6 months) | |
Secondary | Nasogastric tube complications | Categorical reporting of the incidence of any complications occurring with the nasogastric tube e.g. dislodgement, blockage | Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to tube removal or six months post-transplant, whichever comes first (6 months) | |
Secondary | Height Z-score | Change in height Z-score between groups. Measured using ward stadiometer. | Measured monthly from admission to six months post-transplant (6 months) | |
Secondary | Body mass index (BMI) Z-score | Change in BMI Z-score between groups. Weight and height will be combined to report BMI in kg/m^2 and converted to Z-scores. | Measured monthly from admission to six months post-transplant (6 months) | |
Secondary | Mid-upper-arm circumference (MUAC) Z-score | Change in MUAC Z-score between groups. Measured using ward measuring tape. | Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to six months post-transplant (6 months) | |
Secondary | Overall survival | Percentage of children alive (with death from any cause) 100 days post-bone marrow transplant | Measured for all children at day-100 post-transplant | |
Secondary | Non-relapse mortality | Percentage of children alive (with death not caused by disease relapse) 100 days post-bone marrow transplant | Measured for all children at day-100 post-transplant | |
Secondary | Graft-versus-host disease grade III-IV | Percentage of children with grade III-IV graft-versus-host disease (measured using modified Gluckberg classification) 100 days post-bone marrow transplant | Measured for all children at day-100 post-transplant | |
Secondary | Gastrointestinal graft-versus-host disease | Percentage of children with gut graft-versus-host disease (measured using modified Gluckberg classification) 100 days post-bone marrow transplant | Measured for all children at day-100 post-transplant | |
Secondary | Calorie intake | Average intake of calories (total kcal intake and kcals/kg) provided from oral, enteral and parenteral nutrition, averaged over 3-days, measured from the hospital's electronic patient records during the bone marrow transplant admission, and thereafter once the child is at home from 3-day food diaries recorded once per month. | Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to six months post-transplant (6 months) | |
Secondary | Protein intake | Average intake of protein (total protein intake and grams/kg) provided from oral, enteral and parenteral nutrition, averaged over 3-days, measured from the hospital's electronic patient records during the bone marrow transplant admission, and thereafter once the child is at home from 3-day food diaries recorded once per month. | Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to six months post-transplant (6 months) | |
Secondary | Fluid intake | Average intake of fluid (total fluid intake and ml/kg) provided from oral, enteral and parenteral nutrition, averaged over 3-days, measured from the hospital's electronic patient records during the bone marrow transplant admission, and thereafter once the child is at home from 3-day food diaries recorded once per month. | Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to six months post-transplant (6 months) | |
Secondary | Duration of enteral nutrition | Total number of days enteral nutrition is provided during admission for bone marrow transplant | Measured from admission for bone marrow transplant to tube removal or discharge home post-transplant, whichever comes first. (Hospital admission is usually 3 months) | |
Secondary | Duration of parenteral nutrition | Total number of days parenteral nutrition is provided during admission for bone marrow transplant | Measured from admission for bone marrow transplant to tube removal or discharge home post-transplant, whichever comes first. (Hospital admission is usually 3 months) | |
Secondary | Use of enteral feeding tube | Categorical description of what the enteral feeding tube is used for. Categories include: "Not in use", "Nutrition only", "Medicines only", "Fluids only", "Nutrition & medicines", "Medicines & fluids", "Nutrition, medicines & fluids". | Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to six months post-transplant (6 months) | |
Secondary | Blood copper level | Change in blood copper level (micromol/L) during admission for bone marrow transplant | Measured monthly from admission for bone marrow transplant until the child is discharged home following the transplant (hospital admission is usually 3 months) | |
Secondary | Blood selenium level | Change in blood selenium level (micromol/L) during admission for bone marrow transplant | Measured monthly from admission for bone marrow transplant until the child is discharged home following the transplant (hospital admission is usually 3 months) | |
Secondary | Blood zinc level | Change in blood zinc level (micromol/L) during admission for bone marrow transplant | Measured monthly from admission for bone marrow transplant until the child is discharged home following the transplant (hospital admission is usually 3 months) | |
Secondary | Blood vitamin A level | Change in blood vitamin A level (micromol/L) during admission for bone marrow transplant | Measured monthly from admission for bone marrow transplant until the child is discharged home following the transplant (hospital admission is usually 3 months) | |
Secondary | Blood vitamin E level | Change in blood vitamin E level (micromol/L) during admission for bone marrow transplant | Measured monthly from admission for bone marrow transplant until the child is discharged home following the transplant (hospital admission is usually 3 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03482154 -
Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
|
||
Recruiting |
NCT06080490 -
Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients
|
||
Completed |
NCT03042676 -
Electronic Database for the Follow up of the ATG_FamilyStudy
|
||
Recruiting |
NCT03871296 -
DNA Methylation in Allogeneic Hematopoietic Stem Cell Transplantation.
|
||
Not yet recruiting |
NCT06022445 -
Prospective Validation of CARPET Prognostic Model for Septic Shock After Allo-HSCT
|
||
Recruiting |
NCT04502628 -
Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT
|
N/A | |
Recruiting |
NCT03793517 -
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
|
Phase 2/Phase 3 | |
Completed |
NCT03454568 -
The Patients' Experience After Stem Cell Transplant
|
||
Recruiting |
NCT05466201 -
The Use of Eltrombopag Post HSCT in BMFS
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04080622 -
Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation.
|
Phase 3 | |
Recruiting |
NCT05523336 -
Pro-ADM vs PCT in Patients With Complications Post Hematopoietic Stem Cell Transplantation
|
||
Completed |
NCT03355235 -
Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant
|
||
Completed |
NCT04888286 -
DSAs in Patients Undergoing Allo-HSCT From Mismatched Donors
|
||
Not yet recruiting |
NCT05421416 -
Loratadine for the Prevention of G-CSF-related Bone Pain
|
Phase 2 | |
Recruiting |
NCT04167683 -
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
|
||
Active, not recruiting |
NCT03967665 -
Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution
|
Phase 3 | |
Withdrawn |
NCT05104268 -
Study of a New Medical Device for Oral Mucositis
|
Early Phase 1 | |
Recruiting |
NCT04623424 -
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
|
||
Active, not recruiting |
NCT04669210 -
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
|
Phase 2 | |
Completed |
NCT03489551 -
Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients
|
Phase 4 |